CytomX Therapeutics (CTMX) – Company Press Releases
-
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
-
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
-
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
-
CytomX Therapeutics to Present at Upcoming March Investor Conferences
-
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
-
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
-
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
-
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present at Upcoming November Investor Conferences
-
CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
-
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting
-
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
-
CytomX Therapeutics to Present at Upcoming September Investor Conferences
-
CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
-
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
-
CytomX Therapeutics Announces New Employment Inducement Grants
-
CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
-
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
-
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
-
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
-
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
-
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
-
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
-
CytomX Therapeutics to Present at Upcoming March Investor Conferences
-
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
-
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
-
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
-
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
-
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
-
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
-
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
-
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
-
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
-
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
-
CytomX Therapeutics to Present at Upcoming November Investor Conferences
-
CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
-
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
-
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
-
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
-
CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
-
CytomX Therapeutics Provides Strategic Update
Back to CTMX Stock Lookup
